Immediate treatment leads to lower seizure recurrence at 1 year after randomisation compared with controls (high certainty).
Immediate treatment showed no clear difference in mortality at the end of the compared with controls (high certainty).
Immediate treatment probably leads to higher adverse events (control ‐ placebo) compared with controls (moderate certainty).
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
The review found no eligible studies for this question.
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in total (all‐cause) mortality compared with placebo/no antifungal/any other antifungal (moderate certainty).
Untargeted antifungal treatment with any antifungal drug (systemic… may leads to lower proven invasive fungal infection compared with placebo/no antifungal/any other antifungal (low certainty).
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in superficial fungal infection compared with placebo/no antifungal/any other antifungal (low certainty).
Untargeted antifungal treatment with any antifungal drug (systemic… may leads to lower fungal colonization compared with placebo/no antifungal/any other antifungal (low certainty).
Gabapentin showed no clear difference in treatment withdrawalNumber of participants withdrawn for any reason compared with placebo (moderate certainty).
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimen (moderate certainty).
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in acquired drug resistance compared with standard 6‐month ATT regimen (low certainty).
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimens (moderate certainty).
It is very uncertain whether gatifloxacin‐containing 4‐month ATT regimens changes acquired drug resistance compared with standard 6‐month ATT regimens (very low certainty).
It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).
It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
It is very uncertain whether CLOZAPINE + ZIPRASIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Wen 2015) (very low certainty).
It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).
It is very uncertain whether d4T changes drug resistance compared with AZT (very low certainty).